PIONEERING TREATMENTS FOCUSED ON COUNTERACTING HEART DYSFUNCTION
In collaboration with Amgen, Cytokinetics is developing AMG 594, an investigational, novel, selective, oral, small molecule cardiac troponin activator, as a potential treatment for people with heart failure and other diseases.
In preclinical models, AMG 594 has been shown to increase the ability of the heart to contract by binding to cardiac troponin through an allosteric mechanism that sensitizes the cardiac sarcomere to calcium. Similar to cardiac myosin activation, preclinical research has shown that cardiac troponin activation does not change the calcium transient of cardiac myocytes.
Amgen is currently conducting a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 594 in healthy subjects.